Research and Markets has announced the addition of the "Depression - Pipeline Review, H2 2016" report to their offering.
Depression pipeline therapeutics constitutes close to 177 molecules. Out of which approximately 153 molecules are developed by Companies and remaining by the Universities/Institutes. Our latest report Depression - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Depression, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
Depression is a mood disorder that causes a persistent feeling of sadness and loss of interest. Signs and symptoms include sleep disturbances, including insomnia or sleeping too much, changes in appetite, anxiety, agitation or restlessness and physical problems, such as back pain or headaches. Treatment includes antidepressants, mood stabilizers or antipsychotics.
The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 14, 25, 25, 1, 67, 16 and 2 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 15 and 8 molecules, respectively.
Furthermore, this report also reviews of key players involved in therapeutic development for Depression and features dormant and discontinued projects.
Key Topics Covered:
For more information about this report visit http://www.researchandmarkets.com/research/929k33/depression
View source version on businesswire.com: http://www.businesswire.com/news/home/20161024006411/en/Business Wire
Last updated on: 24/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.